Literature DB >> 29027855

Mesial temporal lobe epilepsy: long-term seizure outcome of patients primarily treated with transsylvian selective amygdalohippocampectomy.

Christian Dorfer1, Thomas Czech1, Susanne Aull-Watschinger2, Christoph Baumgartner3, Rebekka Jung2, Gregor Kasprian4, Klaus Novak1, Susanne Pirker3, Birgit Seidl2, Harald Stefanits1, Karin Trimmel2, Ekaterina Pataraia2.   

Abstract

OBJECTIVE The aim of this study was to present long-term seizure outcome data in a consecutive series of patients with refractory mesial temporal lobe epilepsy primarily treated with transsylvian selective amygdalohippocampectomy (SAHE). METHODS The authors retrospectively analyzed prospectively collected data for all patients who had undergone resective surgery for medically refractory epilepsy at their institution between July 1994 and December 2014. Seizure outcome was assessed according to the International League Against Epilepsy (ILAE) and the Engel classifications. RESULTS The authors performed an SAHE in 158 patients (78 males, 80 females; 73 right side, 85 left side) with a mean age of 37.1 ± 10.0 years at surgery. Four patients lost to follow-up and 1 patient who committed suicide were excluded from analysis. The mean follow-up period was 9.7 years. At the last available follow-up (or before reoperation), 68 patients (44.4%) had achieved an outcome classified as ILAE Class 1a, 46 patients (30.1%) Class 1, 6 patients (3.9%) Class 2, 16 patients (10.4%) Class 3, 15 patients (9.8%) Class 4, and 2 patients (1.3%) Class 5. These outcomes correspond to Engel Class I in 78.4% of the patients, Engel Class II in 10.5%, Engel Class III in 8.5%, and Engel Class IV in 2.0%. Eleven patients underwent a second surgery (anterior temporal lobectomy) after a mean of 4.4 years from the SAHE (left side in 6 patients, right side in 5). Eight (72.7%) of these 11 patients achieved seizure freedom. The overall ILEA seizure outcome since (re)operation after a mean follow-up of 10.0 years was Class 1a in 72 patients (47.0%), Class 1 in 50 patients (32.6%), Class 2 in 7 patients (4.6%), Class 3 in 15 patients (9.8%), Class 4 in 8 patients (5.2%), and Class 5 in 1 patient (0.6%). These outcomes correspond to an Engel Class I outcome in 84.3% of the patients. CONCLUSIONS A satisfactory long-term seizure outcome following transsylvian SAHE was demonstrated in a selected group of patients with refractory temporal lobe epilepsy.

Entities:  

Keywords:  AED = antiepileptic drug; ATL = anterior temporal lobectomy; EEG = electroencephalography; IED = interictal epileptiform discharge; ILAE = International League Against Epilepsy; MTLE = mesial temporal lobe epilepsy; SAHE = selective amygdalohippocampectomy; selective amygdalohippocampectomy; temporal lobe epilepsy; temporal lobectomy

Mesh:

Year:  2017        PMID: 29027855     DOI: 10.3171/2017.4.JNS162699

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  3 in total

1.  Risk factors for suicidal tendency in people with epilepsy in China: a case-control study.

Authors:  Mintao Lin; Jiani Chen; Sisi Li; Yingjie Qin; Xuruan Wang; Yadong Liu; Ammar Taha Abdullah Abdulaziz; Wenyu Liu; Dong Zhou; Jinmei Li
Journal:  Sci Rep       Date:  2021-02-02       Impact factor: 4.379

2.  Single-Institutional Experience of Chronic Intracranial Electroencephalography Based on the Combined Usage of Subdural and Depth Electrodes.

Authors:  Yutaro Takayama; Naoki Ikegaya; Keiya Iijima; Yuiko Kimura; Suguru Yokosako; Norihiro Muraoka; Kenzo Kosugi; Yuu Kaneko; Tetsuya Yamamoto; Masaki Iwasaki
Journal:  Brain Sci       Date:  2021-02-28

3.  Temporal lobe epilepsy surgery: Piriform cortex resection impacts seizure control in the long-term.

Authors:  Valeri Borger; Motaz Hamed; Majd Bahna; Áttila Rácz; Inja Ilic; Anna-Laura Potthoff; Tobias Baumgartner; Theodor Rüber; Albert Becker; Alexander Radbruch; Florian Mormann; Rainer Surges; Hartmut Vatter; Matthias Schneider
Journal:  Ann Clin Transl Neurol       Date:  2022-07-01       Impact factor: 5.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.